Personalis (NASDAQ:PSNL) Stock Price Down 9.3% – What’s Next?

Personalis, Inc. (NASDAQ:PSNL)’s share price traded down 9.3% during mid-day trading on Friday . The stock traded as low as $6.66 and last traded at $6.6380. 627,854 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,402,346 shares. The stock had previously closed at $7.32.

Analysts Set New Price Targets

PSNL has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research raised their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Finally, Morgan Stanley decreased their target price on Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Personalis Stock Performance

The company has a market capitalization of $663.35 million, a P/E ratio of -6.97 and a beta of 2.02. The stock has a fifty day moving average of $8.47 and a 200 day moving average of $8.37.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. Research analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Personalis in the fourth quarter worth $31,000. Legal & General Group Plc bought a new stake in shares of Personalis in the 2nd quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new stake in Personalis in the second quarter worth about $34,000. Finally, BNP Paribas Financial Markets boosted its holdings in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.